• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pyxis Oncology Inc. (Amendment)

    2/14/23 4:45:46 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYXS alert in real time by email
    SC 13G/A 1 tm236221d10_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    Pyxis Oncology, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    747324101

    (CUSIP Number)

     

    ___________December 31, 2022__________

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    x Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 747324101

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

     

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    5

    SOLE VOTING POWER

     

    0

     

    NUMBER OF

    SHARES 

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    6

    SHARED VOTING POWER

     

    0

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)    ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     

           

     

     

     

    CUSIP No. 747324101

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

     

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH:

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    0

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)    ¨ 

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

     

             

     

     

     

    CUSIP No. 747324101

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

     

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

     

    NUMBER OF

    SHARES 

    BENEFICIALLY

    OWNED BY

    EACH 

    REPORTING

    PERSON

    WITH:

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    0

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    0

     

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)    ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

     

             

     

     

     

    CUSIP No. 747324101

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

     

    (b)       ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING

    PERSON 

    WITH:

    5

    SOLE VOTING POWER

     

    0

     

    6

    SHARED VOTING POWER

     

    0

     

    7

    SOLE DISPOSITIVE POWER

     

    0

     

    8

    SHARED DISPOSITIVE POWER

     

    0 

     

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)    ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

     

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

           

     

     

     

    Item 1(a).Name of Issuer:

     

    Pyxis Oncology, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    150 CambridgePark Drive, Cambridge, MA 02140

     

    Item 2(a).Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    RA Capital Management, L.P. (“RA Capital”)

    Peter Kolchinsky

    Rajeev Shah

    RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    747324101

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

     

     

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount Beneficially Owned:

    See the response(s) to Item 9 on the attached cover page(s).

       
    (b)

    Percent of Class:

    See the response(s) to Item 11 on the attached cover page(s).

       
    (c) Number of shares as to which such person has:
       
      (i)

    sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

         
      (ii)

    shared power to vote or to direct the vote

    See the response(s) to Item 6 on the attached cover page(s).

         
      (iii)

    sole power to dispose or to direct the disposition of

    See the response(s) to Item 7 on the attached cover page(s).

         
      (iv)

    shared power to dispose or to direct the disposition of

    See the response(s) to Item 8 on the attached cover page(s).

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    Exhibit List

     

    Exhibit 1: Joint Filing Agreement

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:February 14, 2023
       
    RA CAPITAL MANAGEMENT, L.P.  
       
    By: /s/ Peter Kolchinsky
      Name:Peter Kolchinsky
      Title:Authorized Signatory
       
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
       
    RA CAPITAL HEALTHCARE FUND, L.P.  
       
    By: RA Capital Healthcare Fund GP, LLC
    Its: General Partner  
       
    By: /s/ Peter Kolchinsky
      Name:Peter Kolchinsky
      Title:Manager

     

     

     

     

    EXHIBIT 1

     

    AGREEMENT

     

    This Joint Filing Agreement, dated as of February 14, 2023, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

     

    Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock $0.001 par value per share of Pyxis Oncology, Inc. beneficially owned by them from time to time.

     

    Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

     

    This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    Executed and delivered as of the date first above written.

     

    RA CAPITAL MANAGEMENT, L.P.  
       
    By: /s/ Peter Kolchinsky
      Name:Peter Kolchinsky
      Title:Authorized Signatory
       
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
       
    RA CAPITAL HEALTHCARE FUND, L.P.  
       
    By: RA Capital Healthcare Fund GP, LLC
    Its: General Partner  
         
    By: /s/ Peter Kolchinsky
      Name:Peter Kolchinsky
      Title:Manager

     

     

     

    Get the next $PYXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PYXS

    DatePrice TargetRatingAnalyst
    11/21/2024Outperform → Mkt Perform
    William Blair
    11/8/2024$13.00Overweight
    Stephens
    8/8/2024$10.00Buy
    Stifel
    5/7/2024$10.00Buy
    Jefferies
    2/9/2024$8.00Buy
    BTIG Research
    1/23/2024$12.00Outperform
    Leerink Partners
    9/5/2023$7.00Outperform
    RBC Capital Mkts
    11/2/2021$16.00Neutral
    B of A Securities
    More analyst ratings

    $PYXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

      - Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy in first half of 2026 - On track to report preliminary data from Phase 1 trial of MICVO in combination with pembrolizumab targeting mul

      5/15/25 7:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology to Participate in Two Upcoming Investor Conferences

      BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences. 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Wednesday, May 21 at 2:05 p.m. ETJefferies Global Healthcare Conference in New York, NY on Thursday, June 5 at 4:55 p.m. ET A live webcast and replay of the fireside chats will be available on th

      5/14/25 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

      Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model indicated strong activity of the cytotoxic Auristatin0101 payload and potential for MICVO monotherapy to drive immunogenic cell death, a key hypothesis for MICVO's mechanism Combination of a mouse analog of MICVO and anti-PD-1 therapy in a syngeneic model resulted in enhanced tumor clearance and longer immunological memory compared to either treatment alone Totality of pre-clinical data presented at AACR 2025 strongly support MICVO's uniqu

      4/25/25 1:17:47 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pyxis Oncology downgraded by William Blair

      William Blair downgraded Pyxis Oncology from Outperform to Mkt Perform

      11/21/24 7:55:42 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Pyxis Oncology with a new price target

      Stephens initiated coverage of Pyxis Oncology with a rating of Overweight and set a new price target of $13.00

      11/8/24 8:24:38 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Pyxis Oncology with a new price target

      Stifel initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $10.00

      8/8/24 6:48:55 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO & COO Connealy Pamela Ann bought $174,364 worth of shares (88,850 units at $1.96) (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      11/27/24 5:09:59 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connealy Pamela Ann bought $14,960 worth of shares (8,000 units at $1.87), increasing direct ownership by 0.99% to 818,532 units (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      9/28/23 4:32:03 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wadhane Jitendra bought $4,675 worth of shares (2,500 units at $1.87), increasing direct ownership by 1% to 226,937 units (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      9/27/23 6:37:45 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Financials

    Live finance-specific insights

    See more
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

      - Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. The Company ended the third quarter of 20

      11/12/24 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

      - Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected

      8/14/24 4:05:00 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

      PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradom

      5/14/24 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

      SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      11/12/24 11:53:51 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

      SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      11/6/24 4:36:24 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Pyxis Oncology Inc. (Amendment)

      SC 13D/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      4/3/24 5:10:59 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pyxis Oncology Inc.

      10-Q - Pyxis Oncology, Inc. (0001782223) (Filer)

      5/15/25 7:41:51 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Pyxis Oncology, Inc. (0001782223) (Filer)

      5/15/25 7:35:33 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pyxis Oncology Inc.

      SCHEDULE 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      5/6/25 4:17:33 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President ,CEO & CMO Sullivan Lara

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:06:50 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Metzger Michael A

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:05:43 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP, Chief Accounting Officer Wadhane Jitendra

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:04:17 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Leadership Updates

    Live Leadership Updates

    See more
    • Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

      BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex

      6/10/24 7:30:00 AM ET
      $PYXS
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

      BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024. "We are thrilled to have Santhosh join the Pyxis Oncology board. Santhosh brings a wealth of business, investment, strategic, and board experience to our team," said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. "Santhosh's guidance, drawing from his experience working across the biopharma industry, will be invaluable as we continue clinical devel

      3/13/24 8:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 1910 Genetics Appoints Dr. Shaan C. Gandhi as Independent Board Director

      Dr. Gandhi is VP and Head of Strategic Partnerships for Pfizer Ignite and will bring clinical, strategic and financial leadership to biotech's board 1910 Genetics, the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Shaan C. Gandhi, MD, DPhil, to its board of directors. Gandhi joins as an independent board director and will provide a critical clinical perspective alongside his extensive background in biotechnology investing and strategic collaboration at a time when 1910 Genetics continues to build pharmaceutical and technology partnerships and advance its own pipeline of AI-derived therapeutics.

      12/19/23 9:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care